Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.

Phase 1 Completed 68 enrolled Celon Pharma SA National Center for Research and Development, Poland · collab

RandomizedSequentialDouble-blindTreatment

Summary

The planned study is to determine the safety and pharmacokinetic properties of CPL207280 compound after single and multiple (two weeks) administration in healthy volunteers.

Timeline

Start: 2020-05-27
Primary completion: 2021-04-01
Completion: 2021-05-05

Publications

Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals. Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CPL207280	Unknown	120 mg	Oral
Subject	Metformin	Small molecule	750 mg	—

Indications

No indication recorded.